Background: Altered microglial markers and morphology have been demonstrated in patients with schizophrenia in post-mortem and in vivo studies. However, it is unclear if changes are due to antipsychotic treatment. Aims: Here we aimed to determine whether antipsychotic medication affects microglia in vivo. Methods: To investigate this we administered two clinically relevant doses (0.05 mg n=12 and 2.5 mg n=7 slow-release pellets, placebo n=20) of haloperidol, over 2 weeks, to male Sprague Dawley rats to determine the effect on microglial cell density and morphology (area occupied by processes and microglial cell area). We developed an analysis pipeline for the automated assessment of microglial cells and used lipopolysaccharide (LPS) treatment (n=13) as a positive control for analysis. We also investigated the effects of haloperidol (n=9) or placebo (n=10) on the expression of the translocator protein 18 kDa (TSPO) using autoradiography with [ 3 H]PBR28, a TSPO ligand used in human positron emission tomography (PET) studies. Results: Here we demonstrated that haloperidol at either dose does not alter microglial measures compared with placebo control animals (p > 0.05). Similarly there was no difference in [ 3 H]PBR28 binding between placebo and haloperidol tissue (p > 0.05). In contrast, LPS was associated with greater cell density (p = 0.04) and larger cell size (p = 0.01). Conclusion: These findings suggest that haloperidol does not affect microglial cell density, morphology or TSPO expression, indicating that clinical study alterations are likely not the consequence of antipsychotic treatment. The automated cell evaluation pipeline was able to detect changes in microglial morphology induced by LPS and is made freely available for future use.
Introduction
Microglia are the resident immune cells of the central nervous system and perform a range of roles, from phagocytic clearing of debris to experience-dependent modulation of synaptic interaction (Tremblay et al., 2010) . In vivo activation of microglia has shown marked changes in morphology and physiology (Chen et al., 2012; Kozlowski and Weimer, 2012) . Time lapse confocal imaging of microglia in brain slices has demonstrated the transition of quiescent cells with a ramified morphology to an amoeboid, neuroinflammatory, activated form (Stence et al., 2001) .
Human imaging utilizing positron emission tomography (PET) of the translocator protein 18 kDa (TSPO) has been used to investigate microglial activation in vivo. In rodent studies, TSPO expression on microglia increases in response to their activation (Converse et al., 2011; Imaizumi et al., 2007) . Patients with schizophrenia show greater relative TSPO binding than matched healthy controls in some Doorduin et al., 2009; van Berckel et al., 2008) but not all studies (Coughlin et al., 2016; Hafizi et al., 2017; Kenk et al., 2015; Takano et al., 2010; van der Doef et al., 2016) , and some studies have reported reductions using second generation tracers (Collste et al., 2017; Notter et al., 2018) . Similar to the PET imaging studies, post-mortem studies of microglia in schizophrenia have reported increased density and/or morphological changes associated with activation in some but not all studies (Bayer et al., 1999; Kreisl et al., 2013; Steiner et al., 2008) . The finding that relative TSPO binding was increased in a cross-sectional study of patients receiving antipsychotic treatment but not in drug-free patients suggests that antipsychotic treatment may affect TSPO levels (Holmes et al., 2016) . Thus, as most of the PET and post-mortem studies included patients with prior or current antipsychotic exposure, antipsychotic treatment is one potential confounding factor in these studies, which could explain inconsistencies.
Recent in vivo animal investigations have shown that antipsychotic administration results in a reduction in cortical volume, measured with water displacement (Dorph-Petersen et al., 2005: haloperidol and olanzapine) and MRI (Vernon et al., 2011 (Vernon et al., , 2014 haloperidol and haloperidol/olanzapine, respectively). Given their phagocytic role, microglia could putatively contribute to cortical volume reductions, and, consistent with this, an inverse relationship between TSPO relative binding and cortical brain volume has been reported in schizophrenia (Selvaraj et al., 2018) . A number of in vitro studies have demonstrated an anti-inflammatory effect of antipsychotics in general (Bian et al., 2008; Hou et al., 2006; Kato et al., 2007 Kato et al., , 2008 Kato et al., , 2011 Seki et al., 2013) , although this has not been confirmed with all antipsychotic medications tested (Hou et al., 2006) . As these studies were conducted in isolated microglial preparations, it is important to determine the effects of antipsychotics in vivo. However, to date, there have only been two experiments published investigating the in vivo effects of antipsychotics on microglia, one administering haloperidol (Cotel et al., 2015) , the other administering risperidone (Zhu et al., 2014) . The haloperidol study, using a dose of 2 mg/ kg/day for 8 weeks via an osmotic minipump, reports an elevation in activation of microglia, while the risperidone study, using an intragastric dose of 0.5 mg/kg/day for 2 weeks, showed an inhibition of microglial activation (assessed by cell density counts) in a prenatal LPS challenge model. LPS is a bacterial cell wall-derived compound and a potent immune stimulus. Acute doses result in a profound central inflammatory response (Hanisch and Kettenmann, 2007; Skelly et al., 2013) . Repeated doses have demonstrated a subtler effect (Chen et al., 2012 ) with a subtler morphological change, similar to the morphology observed in post-mortem studies of schizophrenia tissue. A factor that may contribute to inconsistencies is that microglial density and morphology is notoriously difficult to assess and quantify. The field has traditionally relied on manual counting and regional coverage as an assessment of function and activity levels. However, this is subject to operator variability, making it difficult to replicate across studies, and does not index morphological changes that indicate microglial activation (Kozlowski and Weimer, 2012) . Having tried a number of manual and automated approaches to microglia quantification (Chen et al., 2012; Kozlowski and Weimer, 2012; Morrison and Filosa, 2013; Paolicelli et al., 2011) , many of which require relatively advanced coding abilities with either Matlab or Python (Forero et al., 2010) , we decided a quantification approach using the modular CellProfiler software would be more suitable. The studies conducted using CellProfiler to date have provided many comparative analyses, from in vitro assessment of LPS effects on an immortalised microglial cell line (Figueroa-Hall et al., 2017) , to high-throughput in vivo behavioural drug screening in C. elegans (Wählby et al., 2012) . We have provided example segmentation images from our adapted pipeline in the supplemental material of this article (supplemental Figure 1) , and further examples are available on the CellProfiler website. CellProfiler is freely available from http://cellprofiler.org/, where a variety of pipelines are available. Our own, designed for microglial analysis, can be downloaded as a supplemental folder.
Here we aimed to address two issue, as follows: First we describe here an open access software pipeline for use in CellProfiler TM designed to specifically detect and quantify confocal microglial images. Second, in view of the uncertainty over the effects of antipsychotics on microglia in vivo, using this pipeline we aimed to investigate the effects of clinically relevant haloperidol exposure on microglial activation using microscopy and autoradiography. We hypothesise that haloperidol would elevate microglial density and TSPO expression on the basis of the findings in Cotel et al. (2015) , which used haloperidol at a relatively high dose via osmotic mini-pump; hence, we aimed to test this using a dose and pharmacokinetic profile more representative of the clinical range. We selected haloperidol as our antipsychotic of choice as it is comparable to previous preclinical studies (Vasconcelos et al., 2003; Vernon et al., 2011 Vernon et al., , 2014 , as well as to determine whether there were any D2R antagonist-specific effects on microglial cells.
Experimental procedures

Animals
All experiments were conducted in accordance with the Animals (Scientific Procedures) Act 1986 (ASPA). Animals were housed, four to a cage, in individually ventilated cages at 21°C with a 12-hour light/dark light cycle, with food and water ad libitum. For all experiments, 250-g Sprague Dawley rats were used (Charles River, UK).
Drug administration
Subcutaneous drug pellets (Innovative Research of America, FL, USA) were inserted into animals for 2 weeks, with either a placebo, 0.05-mg, or 2.5-mg pellet, designed to release over 21 days with zero order kinetics. Hence during our 14-day study design 250-g rats would receive ~0.01 mg/kg/day and ~0.48 mg/kg/day haloperidol for 0.05-and 2.5-mg pellets, respectively. Animals were randomised to treatment group at the cage level, and the investigator was blind to group. Pellets were inserted subcutaneously into the scruff, using a standard gauge trochar (Innovative Research America (IRA), FL, USA) while animals were anaesthetised using isofurane (VWR, PA, USA). The D2 occupancy estimations were made from Kapur et al. (2003) , where dose curves for haloperidol are provided. The haloperidol amount used was based on the clinically comparable ranges provided, with higher doses suggested to result in catalepsy. These doses were estimated to produce a cortical D 2 receptor occupancy of ~65% in the 0.05-mg and up to 80% in the 2.5-mg pellet treated animals, which is comparable to occupancies achieved in clinical practice (Kapur et al., 2000 (Kapur et al., , 2003 . As a positive control to determine whether our image analysis pipeline could detect changes in microglia, a separate group of animals received an inflammatory challenge, using lipopolysaccharide (LPS). We administered LPS via an intraperitoneal route to animals via four doses split over 2 weeks (1 mg/kg dose, four times, 3 days apart). This regime was used to produce a less extreme tissue phenotype than you would expect with a single high dose, based on experiments conducted by Chen et al. (2012) .
Blood collection
To confirm pellet release, 2 mL blood samples from rats receiving medication via pellets (12 placebo; 12 at 0.05 mg; 4 at 2.5 mg) were collected for drug level analysis. Blood was collected from the right atrium at the time of sacrifice during cardiac exsanguination. The blood was then stored with ethylenediaminetetraacetic acid (EDTA) at −80ºC until antipsychotic analysis was conducted.
Blood drug level analysis
Haloperidol was quantified in whole rat blood using haloperidol d 4 to internally standardize the procedure. Whole blood (100-µL aliquot) was subjected to protein precipitation using acetonitrile containing the internal standard. The supernatant from the samples was evaporated to dryness under nitrogen and the residue reconstituted in 100 µL of 0.05% formic acid. Aliquots of 10 µL were injected for analysis and quantification using high performance liquid chromatography-mass spectrometry with multiple reaction monitoring (MRM haloperidol m/z 376 to 165 and haloperidol d4 m/z 380 to 169). The liquid chromatography-mass spectrometry (LC-MS/MS) system was a CTC DLW autosampler (Jasco LC and ABSciex API4000 tandem mass spectrometer). Calibration standards containing haloperidol in whole blood plasma were prepared in duplicate at 0, 0.1, 0.25, 0.5, 1.0, 5.0, 10.0, 50.0 and 100.0 ng/mL, and the samples were analysed with duplicate quality control samples prepared at 0.3, 8 and 75 ng/ mL. Analysis was performed at ABS laboratories (Hertfordshire, UK), and standard FDA (US Food and Drug Administration) and EMA (European Medicines Agency) criteria were applied as dose standards for the analysis batches.
Autoradiography
Placebo-and 0.05-mg-pellet administered animals (n= 9 and n= 10 respectively) were terminally anaesthetized prior to guillotine decapitation. The brains were dissected, rinsed in phosphate buffered saline (PBS) and large vessels and meninges were removed before snap-freezing in isopentane (-25 to −30ºC) on dry ice. Thick coronal sections (20 µm) containing the prefrontal cortex were cut on a Leica cryostat and thaw mounted on 1% gelatinized superfrost slides. Sections were incubated in assay buffer (50 mM Tris-base, 140 mM NaCl, 1.5 mM MgCl 2 , 5 mM KCL, 1.5 mM CaCl 2 , pH 7.4, ambient temperature) with 6 nM [ 3 H]PBR28 (Gifted David Owen, specific activity 3TBq/mmol, Tritec) for 90 minutes to determine total binding. Total binding was measured in adjacent sections, incubated in buffer containing 6 nM [ 3 H] PBR28 for 90 minutes. Non-specific binding was measured in adjacent sections incubated in buffer containing 6 nM [ 3 H] PBR28 and an excess of an unlabeled TSPO ligand; 10 µM unlabeled PK11195 (Sigma-Aldrich, Dorset, UK). To remove the free ligand, slides were rinsed twice for 1 minute in ice-cold wash buffer (50 mM Tris-base, 1.4 mM MgCl 2 , pH 7.4, 4°C) then briefly submerged in ice-cold reverse osmosis (RO) water prior to being rapidly dried in a cool air stream. Sections were apposed to Carestream Kodak Biomax Light film (Sigma-Aldrich) adjacent to tritium microscale standards (American Radiolabeled Chemicals) for 8 weeks before the autoradiograms were developed and analyzed using MCID Basic 7.0 software (Interfocus, Cambridge, UK). A standard curve was derived from densitometry of the adjacent tritiated standards corrected for the specific activity of the radioligand. Specific binding (fmol/mg tissue) was calculated by subtracting the non-specific from total binding. For each brain, specific binding was measured across three coronal sections and the mean specific binding concentration calculated.
Immunohistochemistry
Animals were terminally anaesthetised prior to transcardial perfusion with paraformaldehyde (PFA). Animals were rinsed with 100 mL of 0.1 M PBS, followed by 150 mL of 4% PFA (made up in 0.1 M PBS). Brains were dissected, transferred to 4% PFA and stored at 4ºC. The following day brains were transferred to 30% sucrose solution (made in 0.1 M PBS) for cryoprotection. Brains were uniformly trimmed for cerebral assessment prior to flash freeze embedding in OCT (optimum cutting temperature). Sagittal sections (25 µm), within 1 mm of the midline, were cut on a Leica cryostat and collected on superfrost slides (VWR) for immunohistochemical analysis. Antibody stains were applied in PBS-TX-AZ solution on PBS washed (3, 5-minute cycles) slides. Primary antibody (1:1000 goat anti-Iba-1 Abcam, UK) was applied and incubated over night at 4ºC. Slides were washed with PBS before incubation with the secondary antibody (1:1000 Cy3 donkey anti-goat, Jackson, PA, USA) at room temperature for 2 hours. Slides were washed with PBS and cover slips were mounted using Vectorshield HardSet with an incorporated DAPI stain (Vector Laboratories, CA, USA).
Image acquisition
Images were acquired on a Leica SP5 confocal microscope in sessions with batch matched experimental and control tissue. Series of 10-µm deep Z stacks with 11 optical sections were acquired from the prefrontal cortex (Fillman et al., 2013 ) using a 20× objective (Kozlowski and Weimer, 2012) . At least three images were acquired from a minimum of two brain sections for each rat, with 775-µm 2 regions of interest (ROIs) acquired using bidirectional scanning, with 3 line averaging at 400 Hz. A higher zoom was used in a sub-set of images (ROI area=387.5 µm 2 ) to test the ability of the software to analyse objects of different sizes. Data were spatially normalized to account for different zoom factors (data outputs were normalized by a conversion factor to 1 mm 2 space, for example 775 × 775 µm images were multiplied by 1.6649 to convert to a 1 × 1 mm image space) and imaging was conducted blind to group with case-control matching in sessions to account for laser drift and age of tissue.
Image analysis
The software pipeline was developed to identify microglia based on size parameters. Initial segmentation of microglial-like staining was combined with a DAPI channel to ensure whole cells were being counted. Supplemental figure 1 shows the pipeline steps as a schematic diagram. We quantified cell process occupation of the ROI, cell soma area, cell density and total numbers of nuclei (Kozlowski and Weimer, 2012 ) using a custom CellProfiler TM based analysis pipeline (available through the supplemental files with this article). Maximum projections were generated from .lif image series using a Fiji macro prior to being imported to CellProfiler TM . DAPI nuclei were segmented and counted using CellProfiler TM , alongside microglia. Process occupation was defined as the total area of an ROI occupied by microglial cells (including both processes and cell bodies). Cell area was defined as the average area of the soma and the largest branches associated with the soma, but not the whole tree of processes, for cells in the ROI. Finally cell density was defined as the number of microglial cells in the ROI with a DAPI-stained nucleus overlapping the cell staining.
Post-mortem cerebral analysis
Brains were uniformly trimmed by an investigator blinded to group before morphological assessment. Cranial nerves and olfactory bulbs were removed and the spinal cord was trimmed to the base of the cerebellum. Whole brain mass was determined using a calibrated scale with an accuracy of 0.01 g. Cerebral volume was measured using the Archimedes' principle of fluid displacement with respect to water in a finely graduated cylinder, accurate to 0.25 cm 3 as previously described (Dorph-Petersen et al., 2005) .
Statistics
Statistical analyses were performed using SPSS 22 (IBM, USA). Group comparisons of average cell density and morphology analyses were performed with a one-way ANOVA and a Bonferroni post hoc comparison. Similarly, body weights and brain morphology measurements were assessed using a one-way ANOVA with Bonferroni post hoc comparison. A two tailed t-test was used to compare autoradiography measures. The alpha threshold was set at p<0.05 two tailed.
Results
An automated cell evaluation pipeline to analyse microglial morphology
In order to eliminate bias and improve user reproducibility in the analysis of microglial morphology, we developed an automated software based on CellProfiler TM (supplemental Figure 1) . To validate the software we administered four doses of LPS to rats over a 2-week time course. Figure 1 shows the results of the microglial density and morphological analysis. LPS was administered to 13 animals as a positive control. In tissue from LPStreated animals, cell density (mean cells/mm 2 ± SEM: placebo, 125.18 ± 9.55; LPS, 165.80 ± 10.87; F=7.587; df=1,31; p=0.010) and cell area (mean µm 2 ± SEM: placebo, 144.89 ± 20.54; LPS, 242.04 ± 46.87; F=4.584; df=1,31; p=0.040) were significantly elevated compared with placebo; however, there was no difference in total process area (mean µm 2 ± SEM: placebo, 34845.68 ± 7094.75; LPS, 49029.07 ± 6252.34; F=1.948; df=1,31; p=0.144).
Haloperidol does not affect gross brain structure and microglia morphology and density
We first analysed potential effects of two different doses of haloperidol (~0.01 mg/kg/day and ~0.48 mg/kg/day, see Experimental procedures ) on brain structure. To confirm the presence of haloperidol in the treated animals, we directly measured antipsychotic drug levels in both antipsychotic-treated and placebo groups (n =12, 12 and 4 for placebo, 0.05 mg haloperidol and 2.5 mg haloperidol, respectively). Plasma haloperidol levels for the 0.05 mg/kg group were: mean ± SEM 0.23 ng/mL ± 0.03; and for the 2.5 mg/kg group they were: mean ± SEM 0.75 ng/mL ± 0.01 (detection limit = (0.1 ng/mL)). No haloperidol was detected in placebo pellet-dosed animals. Body weight was not different across experimental conditions (supplemental Figure  2) . Extra-pyramidal effects, catalepsy or vacuous chewing movements were not observed.
Haloperidol did not alter the brain mass at either dose (mean g ± SEM: placebo, 2.16 ± 0.05; 0.05-mg pellet, 2.10 ± 0.05 and 2.5-mg pellet, 2.20 ± 0.05; F=0.71; df=2,36; p=0.50) . However, total brain volume was reduced in the 0.05-mg, but not 2.5-mg, pellet group compared with placebo (mean cm 3 ± SEM: placebo, 1.91 ± 0.07; 0.05-mg pellet, 1.58 ± 0.09 and 2.5-mg pellet, 2.00 ± 0.11; F=6.01; df=2,36; p=0.006 (p=0.014 post hoc Bonferroni vs placebo)), which resulted in an elevation in brain density (mean g/cm 3 ± SEM: placebo, 1.15 ± 0.03; 0.05-mg pellet, 1.38 ± 0.10 and 2.5-mg pellet, 1.12 ± 0.05; F=5.10; df=2,36; p=0.011 (p=0.018 post hoc Bonferroni vs placebo) Figure 2) . DAPIstained nuclei in the prefrontal cortex, also quantified using Cell Profiler, were not different across groups (supplemental material Figure 3 ).
We next studied the effect of haloperidol administration on microglial morphology and density. There was no significant difference between placebo, 0.05 mg/kg or 2.5 mg/kg groups in area occupied by microglial processes (mean µm 2 4.99 and 2.5-mg pellet, 155.41 ± 32.10; F=1.52; df=2,36; p=0.233 (Figure 3) ).
The effects of haloperidol on ligand binding to TSPO
No significant difference was seen between placebo and the 0.05 mg haloperidol group (mean fmol/mg ± SEM: placebo= 109.80 ± 7.54; 0.05 mg haloperidol = 95. 13 ± 11.02; F=1.15; df=1,17; p=0.30 (Figure 4) ), consistent with the microglial morphology and density results.
Discussion
In this investigation we have demonstrated that the antipsychotic medication haloperidol, at two different clinically relevant doses, does not significantly alter microglial cell density, morphology or TSPO expression. The [ 3 H]PBR28 autoradiography, showing no alteration in TSPO expression, supports our microglial density and morphology analyses, and also suggests that antipsychotic treatment does not explain elevations Doorduin et al., 2009; van Berckel et al., 2008) or reductions (Collste et al., 2017; Notter et al., 2018) in [ 11 C]PBR28 or other TSPO PET tracers seen in some clinical studies or post-mortem tissue studies (Fillman et al., 2013; Steiner et al., 2008) .
Our findings extend prior in vivo studies of the effects of antipsychotic drugs on microglia in two translational aspects. Firstly, we used more clinically relevant dosing regimens in comparison to Cotel et al., although we acknowledge that our dosing regimen does not fully reproduce the duration of treatment some patients receive. Our endpoint blood analysis revealed comparable plasma levels of haloperidol to those seen in patients in clinical practice (Coryell et al., 1998) and during experimental monitoring (Lim et al., 2013) , which supports our course of therapy as relevant to doses used in patients. Secondly, we measured TSPO expression using a ligand used in human PET imaging studies. The Cotel et al. study used a much higher dose (2 mg/kg/ day) of medication over a longer duration compared to our study and found elevations in microglial parameters (Cotel et al., 2015) . Taken together with our findings this suggests that while doses in the standard clinical range do not alter microglial parameters, high doses may result in microglial morphological changes.
We observed a reduction in total brain volume in response to the lower dose of haloperidol, in line with previous reports (Dorph-Petersen et al., 2005; Tost et al., 2010; Vernon et al., 2011) . Conversely, there was no significant change in total brain volume seen in rats treated with the higher dose of haloperidol. Our endpoint blood-level analysis confirmed release of haloperidol, hence we expected a similar result. Human equivalent doses of haloperidol would be estimated to be a consistent 0.016 mg/ kg and 0.077 mg/kg (US Department of Health and Human Services, Food and Drug Administration, 2005) . This would be expected to give rise to 65% D2 occupancy at the lower dose and up to 80% in the higher dose context (Kapur et al., 2003) . While acute D2R blockade can cause reversible reductions in striatal volume (Tost et al., 2010) , chronic blockade has been shown to have opposite effects (Parish et al., 2002) . It is possible that the volume changes observed between the two doses reflects the transition from acute to chronic D2R blockade. We also do not see a difference in the total number of cells present, as quantified through DAPI+ nuclear counts, in either group, suggesting antipsychotic treatment does not alter total cell number.
It is interesting and useful to see how cell size and density measures differ from the total area covered by processes ( Figure  1 ). It is unsurprising that there are subtle differences in these approaches. Percentage cover of processes has been used as an assessment criteria of microglia for many years (Trapp et al., 2007) ; however, it seems that more subtle changes may not be well represented. Where all processes are being assessed rather than those associated with a nucleus, cell fragments outside the imaged volume may mask more subtle changes associated with a treatment condition. This study also provides proof-of-concept for an automated approach to analysing microglial density and morphology, and demonstrates its ability to detect changes using LPS administration. This pipeline is freely available for others to use (supplemental files).
Limitations
Haloperidol is a widely used antipsychotic medication and many studies looking at the effects of antipsychotic action have been conducted using haloperidol (Bian et al., 2008; Kapur et al., 2000; Seki et al., 2013; Vernon et al., 2011 Vernon et al., , 2014 . This study has provided useful information about a first generation D2 selective antagonist; however, it would be useful to conduct follow up studies to compare the findings with second generation antipsychotics that exhibit a broader range of receptor antagonism. A number of in vitro studies have demonstrated D2-specific effects of haloperidol on microglial cell culture lines (Bian et al., 2008; Kato et al., 2008) . However, in the present study, we are unable to rule out possible non-D2R effects acting through other receptors. Our results suggest that D2R antagonism does not result in the same effects in vivo as previously demonstrated in vitro.
The risk of a type II error needs to be considered. Nevertheless our study has a larger sample size than the previous two animal investigations of antipsychotics and microglia that detected differences (Cotel et al., 2015; Zhu et al., 2014) . Moreover, the fact we were able to detect changes with the LPS challenge validates the image analyses routine. Though it remains possible that our analyses have missed smaller effects, particularly for process coverage, where LPS did not have a detectable effect suggesting our measure may have lower sensitivity than an acute regime. It should also be recognised that the haloperidol treatment time course, while relatively long in terms of the life-span of a rat, is short compared to the years of treatment some patients receive, and future work is needed to determine if a longer treatment regime would affect the results. Another potential issue is that microglia show an altered response when they have been previously exposed to inflammatory or other stimuli (see review: Calcia et al., 2016; Howes and McCutcheon, 2017) . Thus, the effects of antipsychotics may be different when there has been a prior inflammatory stimulus, as found in the Zhu et al. (2014) study. Finally while we found no evidence of increased [ 3 H] PBR28 binding following haloperidol, we were only able to investigate the 0.05-mg-treated and placebo-treated animals, so it remains possible that higher doses might affect TSPO levels.
Implications
Over the last few decades, a large number of studies have compared the levels of various inflammatory markers between patients with schizophrenia and healthy controls. These studies include analysis of peripheral bloods (Miller et al., 2011 (Miller et al., , 2013 Pillinger et al., 2018) and PET imaging data (De Picker et al., 2017) , as well as post-mortem tissue (van Kesteren et al., 2017) . While there is large heterogeneity in both the sample populations and findings, the results generally indicate microglial changes associated with schizophrenia. A common limitation raised by many of these studies is the presence/history of various antipsychotics whose actions may alter or account for these microglia changes. Our study represents a step in separating the actions of a commonly used first generation antipsychotic on microglial changes from those elicited by the disease. Our results indicate that the D2R-selective antagonist haloperidol does not directly elicit a response in the microglial cell population in the rat cortex. These findings suggest that microglial-associated changes, i.e. either causing microglial activation or having anti-inflammatory effects that mask microglial activation seen in human populations, are unlikely to be due to antipsychotic treatment. A caveat to this is that patients may take medication for longer than we used here, and, as haloperidol is a relatively selective dopamine D 2/3 receptor blocker, it remains possible that antipsychotic drugs with actions at other receptors may have effects on microglia. There is also the possibility that in the context of psychosis, antipsychotics and microglia interact in a different way to that in the healthy brain. Notwithstanding these caveats, our findings also support the use for anti-inflammatory strategies to augment treatment for schizophrenia where inflammation is evident Doorduin et al., 2009; van Berckel et al., 2008) .
In publishing the pipeline we are making the specific modules used here available for the field as a whole. This will save researchers a considerable amount of time and effort when analysing glial cells as they would not have to rely on more labourintensive methods (Kozlowski and Weimer, 2012; Paolicelli et al., 2011 for discussion) . A limitation we have discovered while using the CellProfiler approach is that the image quality required for analysis is overall higher than those often used for manual counting.
Conclusion
This study suggests that at clinically relevant doses, the D 2/3 -selective antipsychotic medication haloperidol does not affect microglial cell density, gross morphology or TSPO expression over a 2-week time course in rats.
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